UnknownPhase 1NCT03882437
Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B
Studying Danon disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rocket Pharmaceuticals Inc.
- Principal Investigator
- Joseph Rossano, MDChildren's Hospital of Philadelphia
- Intervention
- RP-A501(biological)
- Enrollment
- 7 enrolled
- Eligibility
- 8 years · MALE
- Timeline
- 2019 – 2025
Study locations (3)
- University of California, San Diego, La Jolla, California, United States
- University of Colorado, Aurora, Colorado, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03882437 on ClinicalTrials.govOther trials for Danon disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06214507Danon Disease Natural History StudyRocket Pharmaceuticals Inc.
- RECRUITINGPHASE2NCT06092034A Gene Therapy Study of RP-A501 in Male Patients With Danon DiseaseRocket Pharmaceuticals Inc.
- RECRUITINGNANCT07336394Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance TechniquesChinese Academy of Medical Sciences, Fuwai Hospital